Key Points. Pola-DA-EPCH-R has an acceptable safety profile that is similar to previously published results of the standard DA-EPOCH-R regimenSubstituting vincr
Small phase II trial looking at efficacy and safety of Pola-DA-EPCH-R. Although responses look promising 28% of patients had serious adverse events including a colonic perforation and grade 5 sepsis. Given the limited data to support the EPOCH backbone, and known increased toxicities (including deaths when added to VEN), I am not sure it should be the backbone for novel strategies.